Mallinckrodt plc (MNK) Shares are Up 6.47%

Mallinckrodt plc (MNK) : Traders are bullish on Mallinckrodt plc (MNK) as it has outperformed the S&P 500 by a margin of 11.28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.82%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.47% in the last 1 week, and is up 18.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Mallinckrodt plc (NYSE:MNK): The stock opened at $67.53 on Friday but the bulls could not build on the opening and the stock topped out at $68.00 for the day. The stock traded down to $65.85 during the day, due to lack of any buying support eventually closed down at $66.49 with a loss of -1.54% for the day. The stock had closed at $67.53 on the previous day. The total traded volume was 945,199 shares.


The stock has recorded a 20-day Moving Average of 8.59% and the 50-Day Moving Average is 9.1%. Mallinckrodt Public Limited Company is up 0.33% in the last 3-month period. Year-to-Date the stock performance stands at -10.91%.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.